Boston Scientific Corp. is acquiring Swiss medical technology company Symetis SA for $435 million in upfront cash.

Symetis, which has about 300 employees worldwide, is in the business of heart implants. Its portfolio includes the Acurate TA and Acurate neo/TF valve systems for treating patients with aortic valve stenosis, the narrowing of the aortic valve in the heart.

The acquisition is projected to close during the second quarter of 2017, subject to closing conditions.

Boston Scientific also recently acquired some of Neovasc Inc.'s manufacturing assets, in line with the company's investment in structural heart solutions.